Zalifrelimab

Phase 2Monoclonal antibody

AAgenus Inc.

Zalifrelimab is one of 152 small molecule programs targeting Newly Diagnosed. It is currently in Phase 2.

Indications

Total Trials

Active Trials

151

Competitors

Pipeline

Status by Indication[3][1]

Indication

Newly DiagnosedRecruiting

Soft Tissue SarcomaRecruiting

Pancreatic CancerActive, not recruiting

ALSRecruiting

Newly DiagnosedPhase 1

Recruiting

Soft Tissue SarcomaPhase 2

Recruiting

Pancreatic CancerPhase 2

Active, not recruiting

ALSPhase 2

Recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Zalifrelimab

AAgenus Inc.

Phase 2

1 2

Byetta

AstraZeneca

Preclinical

1 3

Medrol

Pfizer

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Active Comparator

Moderna

Preclinical

1 10

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Newly Diagnosed

NCT04943848

Q4 2027

Phase 2Recruiting

Soft Tissue Sarcoma

NCT04028063

Q1 2028

Phase 1/2Recruiting

ALS

NCT06782555

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Active, not recruiting·NNelum Corp·Phase 1/2·NCT04827953·28 enrolled

Refractory Cancer1 trial

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Completed·AAgenus Inc.·Phase 1/2·NCT02694822·89 enrolled

Soft Tissue Sarcoma1 trial

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT04028063·65 enrolled

Treatment1 trial

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Available·AAgenus Inc.··NCT05572970

ALS1 trial

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

Recruiting·IImmunoGenesis·Phase 1/2·NCT06782555·71 enrolled

2 more indications

Newly Diagnosed1 trial

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Recruiting·—·Phase 1·NCT04943848·36 enrolled

Cervical Cancer1 trial

A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors

Completed·AAgenus Inc.·Preclinical·NCT03495882·175 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Zalifrelimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zalifrelimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zalifrelimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Agenus Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: AAgenus Inc.

Zalifrelimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Pancreatic Cancer1 trial

Refractory Cancer1 trial

Soft Tissue Sarcoma1 trial

Treatment1 trial

ALS1 trial

Newly Diagnosed1 trial

Cervical Cancer1 trial

References

Drug Info

Quick Facts

Related News